Uncategorised - European Medical Journal

MASH Redefined: Insights from the EASL Congress 2025

THE EUROPEAN Association for the Study of the Liver (EASL) Congress 2025, Amsterdam, the Netherlands, placed patients and…

Mitigation of Immune Dysfunction in Patients with Hepatitis B after siRNA Treatment

A chronic hepatitis B (CHB) infection is characterised by host immune dysfunction related to a high viral antigen load. The restoration of…

Albumin Therapy for Decompensated Cirrhosis: EASL Congress 2025

THE MANAGEMENT of decompensated cirrhosis remains a formidable challenge in hepatology, owing to its multifaceted complications…

Hepatocyte–Neutrophil Interaction Is Key in the Pathogenesis of Alcohol-Associated Hepatitis

Alcohol-associated hepatitis (AH) is the most severe form of alcohol-related liver disease (ALD), which is characterised by an impairment…

EASL 2025 Abstract Highlights

The following highlights showcase late-breaking research presented at the European Association for the Study of the Liver (EASL) Congress…

Pregnancy and Liver Disease: A Multidisciplinary Challenge

AT THIS year’s European Association for the Study of the Liver (EASL) Congress 2025, held in Amsterdam, the Netherlands…

EAACI 2025 Interview: María Torres

The focus of the EAACI Congress 2025 program is planetary health and a sustainable future. We anticipate that our Congress in Glasgow, UK…

Methotrexate Intolerance Not Tied to Administration Route

In a new cross-sectional study, methotrexate intolerance in patients with rheumatoid arthritis (RA) was not significantly associated with dosing frequency or route of administration, according to new findings.

Gut–Skin Axis Targeted by Herbal Remedy in Atopic Dermatitis Trial

A randomized controlled trial has found that Bojungikgi-tang (BJT), a traditional East Asian herbal medicine, significantly improved symptoms of anorexia and atopic dermatitis (AD) while altering the gut microbiome in affected patients.

Combination Therapy Improves Survival in Liver Cancer

Results showed that patients receiving the combination therapy experienced a median progression-free survival of 5.8 months, compared with 4.0 months.